06th week of 2022 patent applcation highlights part 23 |
Patent application number | Title | Published |
20220041514 | METHOD FOR FABRICATING PERFECTLY WETTING SURFACES - A method of preparing a substrate having a wetting surface, including confirming the presence of an open, interconnected pore network in a ceramic substrate to be wetted with a first metal, filling the open, interconnected pore network with a second metal, | 2022-02-10 |
20220041515 | Processes for Preparing Porous Ceramics for Acoustic Transducers - A process for preparing a porous ceramic body includes forming a green body with a mixture of ceramic material powder, binder material, and pore-forming particles. The process further includes extracting the binder material, decomposing the pore-forming particles, and removing residual organic materials from the green body at respective, progressively higher pre-firing temperatures. After these three stages, the green body is sintered at a still-higher temperature to form the porous ceramic body. Embodiments facilitate manufacturing and can render most or all surface grinding unnecessary, allowing electrode deposition directly onto substantially non-porous surfaces of the porous ceramic body that are naturally formed during sintering. Advantageously, the green body may be formed into net shape by injection molding the mixture that includes the pore-forming particles, and embodiments can result in porous ceramic bodies that are much thicker than currently available, with better structural integrity. | 2022-02-10 |
20220041516 | METHOD FOR SELECTING THE COMPOSITION OF A CONSTRUCTION MATERIAL COMPRISING AN EXCAVATED CLAY SOIL, METHOD AND SYSTEM FOR PREPARING SUCH A CONSTRUCTION MATERIAL - The invention relates to a method ( | 2022-02-10 |
20220041517 | PRODUCTION OF FOUNDRY PREMIX COMPOSITION - A method of preparing a unique foundry premix composition that has a low bulk density of 30-45 lbs/ft | 2022-02-10 |
20220041518 | NANO MODIFIED SILICATE CAPILLARY CRYSTALLINE MATERIAL AND USE METHOD THEREOF - A concrete durability protection method is provided, including following steps: Step one: rinsing the concrete surface; Step two: spraying agent A material or alternately spraying agent B material and agent A material at the wet surface of the concrete; Step three: repeating step two. The beneficial effects of the present invention include: nanoscale active silicate penetrates into the concrete surface layer within a certain depth and reacts with free calcium ions within the concrete to form C—S—H crystalline, thereby improving the compactness of the concrete surface layer within a certain depth, repairing defects in the concrete surface layer within a certain depth, such as the capillary interstices, pores, microcracks, etc., so as to effectively improve the durability of concrete. The unreacted nanoscale active silicate material has permanent activity. It could recover its activity when the concrete absorbs moisture, and continue to react with free calcium ions in the concrete to quickly form C—S—H crystals, realizing the permanent concrete durability protection. | 2022-02-10 |
20220041519 | METHOD FOR REPAIRING COMPOSITE COMPONENTS USING FILLER MATERIAL - A method for repairing composite components includes positioning repair material within a repair region of a composite component formed of a composite material. Furthermore, the method includes filling a feature defined by the composite component with a filler material, with the filler material being a precursor to the composite material. Additionally, after filling the feature with the filler material, the method includes infiltrating the composite component with an infiltrant to densify the repair region and the filler material such that the feature is filled with new material. | 2022-02-10 |
20220041520 | Compositions for Increasing Nitrogen Sources Life Span in Plant Growth Mediums and Methods of Making - The present invention relates to compositions for increasing a nitrogen source life span in plant growth mediums as well as methods of making these compositions. The invention also relates to compositions and methods of reacting a nitrogen source with one or more nitrification inhibitors using standard equipment for producing nitrogen sourced particles. | 2022-02-10 |
20220041521 | WATERLESS ELECTRICALLY OPERATED PROPELLANT - An electrically operated propellant includes a perchlorate oxidizer and a water insoluble polymeric binder with a water solubility of less than 0.1 grams (g) per 100 grams water at 25° Celsius (° C.). The electrically operated propellant is substantially waterless with a water content of less than 10 weight % (wt. %) water based on total weight of the electrically operated propellant. | 2022-02-10 |
20220041522 | WATERLESS ELECTRICALLY OPERATED PROPELLANT - An electrically operated propellant includes an electrolyte source. The electrolyte source is an ionic liquid, a polyelectrolyte, or a combination thereof. The electrically operated propellant also includes a polymeric binder. The electrically operated propellant is substantially waterless with a water content of less than 10 wt. % water based on total weight of the electrically operated propellant. | 2022-02-10 |
20220041523 | Passivated Fuel - A non-self-passivating fuel such as boron or magnesium is protected from exposure to oxygen sources by a self-passivating fuel layer such as aluminum or titanium. When the non-self-passivating fuel is utilized within a layered structure of alternating fuel and oxygen source layers, self-passivating fuel layers located between each non-self-passivating fuel layer and each oxygen source layer. The self-passivating fuel oxidizes until self-passivation is reached, protecting the non-self-passivating fuel from oxidation. Any of the non-self-passivating fuel which does not oxidize is available for use as fuel in any fuel-oxygen source reaction. | 2022-02-10 |
20220041524 | A WATER-BASED EXPLOSIVE - An explosive, in particular a water-in-oil emulsion explosive, comprising a water-based explosive composition and a gas, wherein the gas is infused with two different ranges of sizes of nanobubbles, to provide controlled hotspots for detonation to improve emulsion stability and detonation sensitivity. Into the Nano Bubble tank ( | 2022-02-10 |
20220041525 | LOW-ENERGY CONSUMPTION METHOD FOR DEHYDRATING ETHANOL INTO ETHYLENE - A process for dehydrating an ethanol feedstock to give ethylene, includes: | 2022-02-10 |
20220041526 | BASE OIL SYNTHESIS VIA IONIC CATALYST OLIGOMERIZATION AND WATERLESS SEPARATION OF THE OLIGOMERIZATION CATALYST - Described herein is a base oil synthesis via ionic catalyst oligomerization further utilizing a hydrophobic process for removing an ionic catalyst from a reaction mixture with a silica gel composition, specifically a reaction mixture comprising an oligomerization reaction to produce PAO utilizing an ionic catalyst wherein the ionic catalyst is removed post reaction. | 2022-02-10 |
20220041527 | NAPHTHA COMPLEX WITH THERMAL OXIDATION SYSTEM - A process for treating effluent streams in a naphtha complex is described. One or more of the sour water stripping unit for the NHT sour water from the NHT, the amine treatment unit and the caustic treatment unit for the NHT stripper off-gas, the caustic scrubber unit or other chloride treatment unit for the off-gas from the C | 2022-02-10 |
20220041528 | SYSTEM FOR RECOVERY OF PROPYLENE FROM A PROPANE DEHYDROGENATION PROCESS - In a propane dehydrogenation (PDH) process, the purpose of the deethanizer and chilling train systems is to separate the cracked gas into a methane-rich tail gas product, a C2, and a C3 process stream. By the use of staged cooling, process-to-process inter-change against propane feed to the reactor and use of high efficiency heat exchangers and distributed distillation techniques, refrigeration power requirements are reduced and a simple and reliable design is provided by the process described herein. | 2022-02-10 |
20220041529 | PROPANE/BUTANE DEHYDROGENATION COMPLEX WITH THERMAL OXIDATION SYSTEM - A process for the treatment of sulfidic spent caustic, conditioned catalyst regeneration vent gas, C4 isomerization off gas, various and hydrocarbon containing liquid and gaseous streams in addition to toxic containing streams like cyanidic off gas and waste water in a propane/butane dehydrogenation complex is described. Various effluent streams are combined in appropriate collection vessels, including an off-gas knockout drum, a hydrocarbon buffer vessel, a spent caustic buffer vessel, an optional a waste water buffer vessel, and a fuel gas knockout drum. Streams from these vessels are sent to a thermal oxidation system. | 2022-02-10 |
20220041530 | Method for Preparation of Fluoro Alkylated Compounds by Homogeneous NI Catalysis - The invention discloses a method for the preparation of fluoro alkylated compounds by homogeneous Ni catalyzed fluoro alkylation with fluoro alkyl halides in the presence of a base. | 2022-02-10 |
20220041531 | ONE STEP PROCESS FOR MANUFACTURING TRIFLUOROIODOMETHANE FROM TRIFLUOROACETYL HALIDE, HYDROGEN, AND IODINE - The present disclosure provides a process for producing trifluoroiodomethane (CF | 2022-02-10 |
20220041532 | HYDROFLUOROOLEFINS AND METHODS OF USING SAME - A hydrofluoroolefin compound represented by the following general formula (II): Formula (II) where Rf is a linear, branched, or cyclic perfluoroalkyl group having 1-6 carbon atoms, and optionally comprises at least one catenated heteroatom selected from nitrogen or oxygen; n is 0 or 1; X is Cl or Br; with the following proviso: when Rf is CF3, then n is 1. | 2022-02-10 |
20220041533 | PROCESS FOR PRODUCING 1-(4-ISOBUTYLPHENYL)ETHANOL BY HYDROGENATION OF 1-(4-ISOBUTYL-PHENYL)ETHANONE IN THE PRESENCE OF A CATALYST COMPOSITION COMPRISING COPPER - Described is a process for producing 1-(4-isobutylphenyl)ethanol by reacting 1-(4-isobutyl-phenyl)ethanone with hydrogen in the presence of a catalyst composition comprising cop-per and one or more metals other than copper, and a use of a respective composition and/or of a pre-composition, the pre-composition comprising a mixture of oxides of copper and oxides of one or more metals other than copper, in a catalytic hydrogenation process for producing 1-(4-isobutylphenyl)ethanol from 1-(4-isobutylphenyl)ethanone. | 2022-02-10 |
20220041534 | CUMENE-PHENOL COMPLEX WITH THERMAL OXIDATION SYSTEM - A process for the treatment of waste water, spent air, and hydrocarbon containing liquid and gaseous streams in the cumene/phenol complex is described. Various effluent streams are combined in appropriate collection vessels, including a spent air knockout drum, a hydrocarbon buffer vessel, a fuel gas knockout drum, a phenolic water vessel, and a non-phenolic water vessel. Streams from these vessels are sent to a thermal oxidation system. | 2022-02-10 |
20220041535 | PHENOL DERIVATIVE, AND PREPARATION PROCESS AND USE THEREOF - A phenol derivative of the present invention has a structure as represented by the formula (I): | 2022-02-10 |
20220041536 | ISOMERISATION REACTION - Described herein is a process including isomerizing the β position of a β-trisubstituted C | 2022-02-10 |
20220041537 | Transfer Hydroformylation for the Production of Oxygenates - The present disclosure provides a method for forming oxygenates from olefins which includes hydroformylation of aldehydes as a formyl source alternative to syngas. In at least one embodiment, a hydroformylation process is performed at low-temperature and at or near ambient pressure for the conversion of olefins into aldehydes, thus reducing the formation of by-products such as via double bond or skeletal isomerization of the feedstock; or via further conversion of the formed aldehydes and alcohols. In at least one embodiment, the use of gaseous olefinic products (e.g., ethylene) instead of strained olefins (e.g., norbornene) improves the control equilibria in transfer hydroformylation reactions. | 2022-02-10 |
20220041538 | CANNABIGEROL QUINONE ACID AND SALTS THEREOF - A compound of formula I | 2022-02-10 |
20220041539 | METHODS OF REDUCING COLOR IN ALKANOLAMINE COMPOSITIONS AND COMPOSITIONS PRODUCED THEREBY - A method of reducing color in an alkanolamine, the method comprising: contacting the alkanolamine with an amount of an aqueous solution effective to provide 5 to 1000 parts per million by weight of an alkali metal borohydride, based on parts by weight of the alkanolamine; and 0.5 to 10,000 parts per million by weight of an alkali metal hydroxide, based on parts by weight of the alkanolamine; preferably wherein the color-reduced alkanolamine is not distilled after the contacting. | 2022-02-10 |
20220041540 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS - Provided herein are arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders. | 2022-02-10 |
20220041541 | METAL SALTS AND USES THEREOF - The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof. | 2022-02-10 |
20220041542 | A process for preparation of amides and esters of 2-((2-hydroxypropanoyl)oxy)propanoic acid - The present invention describes method of preparation of esters or amides of lactyl lactates of general formula I, where Z denotes to group of R—O or RR′—N and R represent alkyl, aryl or H from lactide and the lactide is in contact with a hydrocarbyl alcohol and a hydrolyzable halide in a non-chlorinated organic solvent, or an amine initiated by a hydrolysable halide or hydrogen halide solution or an ammonium hydrohalide, wherein the hydrocarbyl alcohol or amine is either aliphatic or aromatic and containing 1 to 1000 carbon atoms, preferably 1 up to 150 carbon atoms, and optionally one or more, preferably 1 to 5, —CH | 2022-02-10 |
20220041543 | BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS - Provided herein are compounds of the formulas: | 2022-02-10 |
20220041544 | AZOBENZENE DERIVATIVE, PREPARATION METHOD THEREOF, AZOPHENYL LIGHT CONTROL REVERSIBLE ADHESIVE AND METHOD OF USING THE SAME - An azobenzene derivative, a preparation method of the azobenzene derivative, an azophenyl light control reversible adhesive, and a method of using the azophenyl light control reversible adhesive are disclosed. The azobenzene derivative has a molecular structure as P1 or P2. In the abovementioned preparation method, the azobenzene derivative P1 or P2 is obtained from an esterification reaction of an azophenyl group, 3,4,5-tripentyloxybenzoic acid or 3,4,5-tri(dodecyloxy)benzoic acid, and 2,2′-dihydroxy-1,1′-binaphthol. The melting point of the azobenzene derivative P1 or P2 is modified commonly by alkyl chains and binaphthol to be slightly higher than room temperature. | 2022-02-10 |
20220041545 | FLUORESCENT COMPOUND FOR DETECTION OF ISOCYANATE SUBSTANCES, PREPARATION METHOD AND USE THEREOF AS TEST-PAPER-TYPE DETECTION PROBE - Disclosed is a fluorescent compound for the detection of isocyanate substances, a preparation method therefor and use thereof as a test-paper-type detection probe. The fluorescent compound is 2,4-di(((4′-(diphenylamino)-[1,1′-biphenyl]-4-yl)imino)methyl)phenol. The fluorescent compound is prepared by means of a one-step method. The fluorescent compound has simple and convenient preparation with high yield, and is capable of making a rapid and specific response to isocyanate substances. Moreover, the fluorescence intensity of the fluorescent compound will enhance with the increase of the isocyanate concentration. The fluorescent compound can be made into a portable test-paper-type probe for the detection of isocyanate substances in air, and can achieve the visual detection of volatile isocyanate gases. The probe has an aggregation-induced emission effect, and thus it has higher fluorescence quantum yield when using a test-paper-type probe for detection. | 2022-02-10 |
20220041546 | INTEGRATED METHODS AND SYSTEMS FOR PRODUCING AMIDE AND NITRILE COMPOUNDS - Provided herein are integrated methods and systems for the production of acrylamide and acrylonitrile compounds and other compounds from at least beta-lactones and/or beta-hydroxy amides. | 2022-02-10 |
20220041547 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection - The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD). | 2022-02-10 |
20220041548 | COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR TREATING HYPERTENSION OR HEART FAILURE - The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma. | 2022-02-10 |
20220041549 | PERFLUOROACYL PEROXIDE PRODUCTION METHOD, AND FLUOROALKYL IODIDE PRODUCTION METHOD - To provide a method for producing a perfluoroacyl peroxide which can suppress formation of solid matters in a reaction apparatus, and a method for producing a fluoroalkyl iodide. | 2022-02-10 |
20220041550 | USE OF AT LEAST ONE HEMI-PEROXYACETAL, ALONE OR IN COMBINATION WITH OTHER PEROXIDES, TO PROMOTE POLYMERISATION OR COPOLYMERISATION OF ETHYLENE UNDER HIGH PRESSURE - The present invention relates to the use of at least one peroxide selected from the group consisting of hemiperoxyacetals, alone or in combination with one or more distinct additional peroxides, for the radical polymerization or copolymerization of ethylene under high pressure. | 2022-02-10 |
20220041551 | METHODS OF TREATING MOOD DISORDERS - Methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds. | 2022-02-10 |
20220041552 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE - The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation. | 2022-02-10 |
20220041553 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 - Disclosed herein are compounds, compositions, and methods for treating neurodegenerative diseases, such as Alzheimer's disease. | 2022-02-10 |
20220041554 | PREPARATION OF SULFONAMIDE HERBICIDE PROCESS INTERMEDIATES - Improved methods for preparing chemical precursors to sulfonyl chloride III, which are important intermediates in the preparation of pyroxsulam herbicide are provided. Specifically, these precursors are compounds of Formulas VII and/or VIII, and IX, wherein R is a C | 2022-02-10 |
20220041555 | METHODS FOR SYNTHESIS OF OXYPICOLINAMIDES - The present technology relates to processes, mixtures and intermediates useful for making fungicide, florylpicoxamid. Also disclosed herein are processes for addition reactions which suppress epimerization and/or racemization. | 2022-02-10 |
20220041556 | Method for Synthesizing Pitavastatin t-Butyl Ester - Method for Synthesizing Pitavastatin t-Butyl Ester A method for synthesizing pitavastatin tert-butyl ester includes obtaining a substance B through reacting (4R-CIS)-6-chloromethyl-2,2-dimethyl-1,3-dioxolane-4-acetic acid tert-butyl ester with a substance A under the action of a first base catalyst, 5 oxidizing with an oxidizing agent to obtain a substance C, then reacting with 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-formaldehyde under the action of a second base catalyst to obtain a substance D, and finally, carrying out an acid deprotection to obtain pitavastatin t-butyl ester. The reaction conditions of the present invention are mild and controllable, and the reaction conditions of the synthesis of the Julia olefination do 10 not require an ultra-low temperature reaction. The operation is convenient and simple, the stereoselectivity is good, the yield is high, and the synthesized pitavastatin t-butyl ester is a completely non-cis isomer, and its purity is high. | 2022-02-10 |
20220041557 | DEUTERATED CFTR POTENTIATORS - This invention relates to compounds of Formula I: | 2022-02-10 |
20220041558 | PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOF - Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib | 2022-02-10 |
20220041559 | BENZO-AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS - The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma. | 2022-02-10 |
20220041560 | PYRIDAZINONE HERBICIDES AND PYRIDAZINONE INTERMEDIATES USED TO PREPARE A HERBICIDE - Disclosed are compounds of Formula I and N-oxides or salts thereof, wherein R | 2022-02-10 |
20220041561 | Amino Pyrimidine Derivatives - The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammartory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancer e.g. of hematopoietic origin or solid tumors. | 2022-02-10 |
20220041563 | Compounds and Compositions for Eye Treatments - This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia. | 2022-02-10 |
20220041564 | Method for Racemisation of (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H isoxazol-3-yl]-2-Methyl-Benzoic Acid - The present invention relates to a method for racemizing (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid. | 2022-02-10 |
20220041565 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS - The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. | 2022-02-10 |
20220041566 | 2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF - Compounds are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR). | 2022-02-10 |
20220041567 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS - The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. | 2022-02-10 |
20220041568 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS - The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (1). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases. | 2022-02-10 |
20220041569 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoaz- uleno[5,6-d][1,3]dioxole - The compound (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole, compositions and consumer products comprising the compound, methods of making the compound, and the various uses of the compound. | 2022-02-10 |
20220041570 | Method for Preparation of Fluoro Alkylated 1,4-Dioxene by Homogeneous NI Catallysis - The invention discloses a method for the preparation of fluoro alkylated 1,4-dioxene by homogeneous Ni catalyzed fluoro alkylation with fluoro alkyl halides of | 2022-02-10 |
20220041571 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OX- OPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF - The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy. | 2022-02-10 |
20220041572 | CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS - The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. | 2022-02-10 |
20220041573 | OREXIN 1 RECEPTOR ANTAGONISTS - The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R | 2022-02-10 |
20220041574 | PYRAZOLE AMINE REACTIVE CRYSTALLIZATION - This application relates to efficient and economical synthetic chemical processes for the preparation of pesticidal thioethers. Specifically, the present application relates to improved reactive crystallization methods for producing compounds useful in the preparation of pesticidal thioethers. | 2022-02-10 |
20220041575 | METHODS OF MANUFACTURING OF NIRAPARIB - Disclosed herein are methods and processes of preparing niraparib and pharmaceutically acceptable salts thereof, and intermediates and their salts useful for the synthesis of niraparib. | 2022-02-10 |
20220041576 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound is provided in the present invention as a class of novel CRL4 | 2022-02-10 |
20220041577 | Heterocyclic Compound as CDK-HDAC Double-Channel Inhibitor - The invention provides compounds of formula (I) as shown below, including their possible enantiomers and diastereomers, as well as pharmaceutically acceptable salts, hydrates or solvates thereof. The invention also provides pharmaceutical compositions of these compounds, methods for their preparation, and their use in the treatment of diseases and disorders (including cancers). | 2022-02-10 |
20220041578 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND - The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4 | 2022-02-10 |
20220041579 | SUBSTITUTED QUINOXALINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES - Provided herein are 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives of the general Formula I; and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X | 2022-02-10 |
20220041580 | CYCLIC COMPOUND FORMED BY FRIEDEL-CRAFTS REACTION AT POSITIONS 1 AND 3 OF CARBAZOLE AND PREPARATION METHOD THEREOF - A cyclic compound formed by a Friedel-Crafts reaction at positions 1 and 3 of carbazole and a preparation method thereof are disclosed. The compound is formed by connecting an achiral type I di-(tertiary alcohol) synthon constructed from fluorenyl and benzene or a derivative thereof, at position 9 of fluorenyl with positions 1 and 3 of carbazole, forming a closed ring structure with a clear and durable shape, having clear side lengths and vertices on the nanometer scale. The cyclic compound has a general structural formula of | 2022-02-10 |
20220041581 | CONDENSED-CYCLIC COMPOUND - The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the formula (I): | 2022-02-10 |
20220041582 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS - Disclosed are compounds of Formula 1, wherein R | 2022-02-10 |
20220041583 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THERE OF - Provided herein is compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. | 2022-02-10 |
20220041584 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS - Novel compounds of Formula I are described, where the compounds are selective HDAC6 inhibitors suitable for treatment of diseases associated with HDAC6, where X, Y, Z, A | 2022-02-10 |
20220041585 | BROMOPHENOL-PYRAZOLINE COMPOUND AND SYNTHESIS METHOD AND USE THEREOF - The present invention relates to a compound, and in particular to a bromophenol-pyrazoline compound and a synthesis method and use thereof. The bromophenol-pyrazoline compound is represented by a general structural formula below: | 2022-02-10 |
20220041586 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS - Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R | 2022-02-10 |
20220041587 | SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHEN- YL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPR- OPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE - Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer. | 2022-02-10 |
20220041588 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS - Provided are certain RET inhibitors, pharmaceutical compositions thereof, and methods of use thereof. | 2022-02-10 |
20220041589 | METHOD FOR PREPARING APIXABAN - The present disclosure relates to a novel method for preparing apixaban. The method of the present disclosure is economical since no expensive reagents or solvents are used. In addition, the method is applicable to mass production on an industrial scale because it requires no special conditions or complicated processes and no hazardous reagents or solvents are used. Furthermore, because no toxic solvent is used in the final step of apixaban synthesis and in a purification process, high-purity apixaban can be prepared stably at high yield without the concern of residual solvents. | 2022-02-10 |
20220041590 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF - This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases. | 2022-02-10 |
20220041591 | COMPOUNDS FOR TREATING DIABETES AND/OR RELATED CONDITIONS - Compounds useful for treating or preventing diabetes and related conditions, and for preventing, inhibiting or reversing amylin-amyloid fibril formation, preventing islets of Langerhans (Beta)-cell death, preventing or reversing the transition from soluble human amylin to insoluble human amylin, preventing and inhibiting or reversing cytotoxic amylin fibril formation. The invention relates to compounds of Formula I and compounds of Formula II: | 2022-02-10 |
20220041592 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS - The present invention encompasses compounds of the formula I | 2022-02-10 |
20220041593 | SYNTHESIS FOR 3-BROMO-5-(2-ETHYLIMIDAZO[1, 2-ALPHA]PYRIDINE- 3-CARBONYL)-2-HYDROXYBENZONITRILE - A method for synthesizing 3-bromo-5-(2-ethylimidazo[1,2-a] pyridine-3-carbonyl)-2-hydroxybenzonitrile, particularly relates to a method for synthesizing a compound represented by a formula (III), and particularly relates to step A or step B; step A: a compound represented by a formula (I) and a compound represented by a formula (II) are first heated in an organic solvent to react, and the resulting reaction product and a base are heated in the presence of water to continue the reaction to obtain a compound represented by a formula (III); and step B: a compound represented by the formula (I), a compound represented by a formula (II), and a base are heated in an organic solvent to react, and the resulting reaction product is heated in the presence of water to continue the reaction to obtain a compound represented by a formula (III). | 2022-02-10 |
20220041594 | PTPN11 INHIBITORS - The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease. | 2022-02-10 |
20220041595 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS - The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitor enantiomers of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, with high enantiomeric excess (% ee). The disclosure also relates to method of using the compound of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer. | 2022-02-10 |
20220041596 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS - The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R | 2022-02-10 |
20220041597 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X - FLT3-ITD and FLT3-TKD are the most frequent mutations in acute myeloid leukemia (AML) with the former associated with a poor prognosis. Here we show that inhibition of the deubiquitinase USP9X by its inhibitor WP1130 or EOAI3402143 (G9) induces apoptosis preferentially in cells transformed by these mutant kinases, including FLT3-ITD-positive AML cell line MV4-11 and primary AML cells. Mechanistically, WP1130 induced aggresomal translocation of the mutant kinases, particularly FLT3-ITD in its activated and autophosphorylated conformation, to block the downstream signaling events, which was aggravated by knock down of USP9X. Moreover, USP9X physically associated with FLT3-ITD to inhibit its K63-linked polyubiquitination, while FLT3-ITD induced tyrosine phosphorylation and degradation of USP9X through the ubiquitin/proteasome pathway. WP1130 or G9 also induced oxidative stress to stimulate stress-related MAP kinase pathways and DNA damage responses to activate in cooperation with inhibition of FLT3-ITD signaling the intrinsic mitochondria-mediated apoptotic pathway, which was synergistically enhanced by BH3 mimetics and prevented by overexpression of Bcl-xL or Mcl-1. Thus, USP9X represents a promising target for novel therapies against therapy-resistant FLT3-ITD-positive AML. | 2022-02-10 |
20220041598 | RIBOCICLIB SALTS AND SOLID STATE FORMS THEREOF - The present disclosure relates to Ribociclib solid state forms, Ribociclib salts including Ribociclib succinate and solid state forms thereof, as well as processes for preparation thereof and pharmaceutical compositions thereof. | 2022-02-10 |
20220041599 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING - Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions. | 2022-02-10 |
20220041600 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS - The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines. | 2022-02-10 |
20220041601 | PYRIMIDINONES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2022-02-10 |
20220041602 | POLYCYCLIC COMPOUND INHIBITING MNK1 AND MNK2 - Provided is a polycyclic compound inhibiting MNK1 and MNK2. Specifically, provided is a compound represented by formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the definition of each group is as described in the description. These compounds can be used for preparing pharmaceutical compositions for the treatment of diseases or disorders related to MNK activity or expression level. | 2022-02-10 |
20220041603 | SRC INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF - The present invention relates to novel SRC inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery. | 2022-02-10 |
20220041604 | SOLID FORMS OF N-(4-FLUORO-3-(6-(3-METHYLPYRIDIN-2-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2- -YL)PHENYL)-2,4-DIMETHYLOXAZOLE-5-CARBOXAMIDE - The application relates to N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide (Compound I) fumaric acid co-crystals and X-ray amorphous complexes of Compound (I) and fumaric acid. The application also provides methods of making the same; pharmaceutical compositions comprising them; and their use in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a kinetoplastid parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease. | 2022-02-10 |
20220041605 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION - This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer. | 2022-02-10 |
20220041606 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 - Described are substituted fused bicyclic pyridinone and pyrimidinone carboxamide positive allosteric modulators of muscarinic acetylcholine receptor M | 2022-02-10 |
20220041607 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE - A fused bicyclic compound having an effect in inhibition of the activity of a tyrosine kinase, and preparation and use thereof are disclosed. In particular, a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a polymorph, a prodrug or an isotopic variation thereof, as well as a pharmaceutical composition including the same are disclosed. As a selective irreversible inhibitor of Bruton's tyrosine kinase, the described compound can be used for preventing or treating diseases such as inflammation, autoimmune diseases (such as rheumatoid arthritis), xenogeneic immune diseases and cancers. | 2022-02-10 |
20220041608 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF - The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention. | 2022-02-10 |
20220041609 | AN IMPROVED ASYMMETRIC SYNTHESIS OF AZASPIRO COMPOUNDS - The present invention relates to an improved asymmetric synthesis of azaspiro or diazaspiro compound (hereafter referred to as the compound 5, (5 | 2022-02-10 |
20220041610 | Fused Tricyclic Pyridazinone Compounds Useful to Treat Orthomyxovirus Infections - The invention provides compounds of Formula (I): | 2022-02-10 |
20220041611 | CRYSTALLINE FORM OF DI-P-TOLUOYL-L-TARTRATE OF UPADACITINIB - The present application provides a upadacitinib salt compound and a preparation method therefor. The salt involved in the method in the present application has an easy preparation operation, a cheap raw material easy to get, and a good purification effect on upadacitinib, and is beneficial to industrial production. | 2022-02-10 |
20220041613 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE - The present disclosure relates to new compounds of formula I | 2022-02-10 |
20220041614 | FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE - A fused tetracyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. A compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B, wherein each variable is as defined in the specification. | 2022-02-10 |
20220041615 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME - The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound according to the present disclosure, an organic electroluminescent device having low driving voltage and/or high luminous efficiency characteristics can be provided. | 2022-02-10 |